Nanoparticles, with their distinct properties that vary from their bulk material equivalent, continue to gain popularity for studies into multi-modal applications in medicine. This research introduces the use of thulium oxide nanoparticles for biological applications and characterizes the potential of this novel nanoparticle for image-guided radiotherapy of brain cancer. In this study, we investigate the structural characteristics of this nanoparticle, and reveal a significant dose enhancement towards radioresistant brain tumour cells in vitro that also underlies an improvement in the CT image contrast of brain tumours in vivo. The thulium oxide nanoparticles utilized in the investigations described in this article were measured to be 40-45 nm from x-ray diffraction and scanning electron microscopy data. In vitro investigations assessed the cell survival and DNA damage in 9 l gliosarcoma cells following irradiation with 150 kVp orthovoltage x-rays. Immediately after the 150 kVp irradiation (15 min) an increase in the number of γ-H2AX induced foci indicates the production of more double-strand DNA breaks. Following from the short time-frame irradiation outcomes, clonogenic cell survival assays confirmed long-term radio-sensitization, with the cell sensitivity increasing by a factor of 1.32 (measured at the 10% survival fraction) for the irradiated 9 l cells exposed to thulium nanoparticles. A simple CT experiment shows that our thulium nanoparticles suspended in water at concentrations >0.5 mg ml −1 (0.05-20 mg ml −1 investigated) are clearly observable against water. Extending the CT experiment to an in vivo investigation, cellular uptake of the nanoparticles was demonstrated through CT image enhancement of the cancer site in 9-to 10-week-old Fisher rats bearing 9 l gliosarcomas, 12 days after cell implantation. The 9 l cancer is clearly visible on the CT image after injecting 40 μg of nanoparticles (2 μl at 20 mg ml −1 ) directly to the cancer site (5.5 mm from the dura and 3.5 mm right laterally of the bregma, 5 mm depth). To our knowledge, this work demonstrates the first application of thulium nanoparticles in biology and medicine, for radiotherapy and image guidance purposes. 
brain cancer does not exceed 52% (Ostrom et al 2015) . 9L gliosarcoma is an animal cell model 48 similar to high-grade human glioma cells and shows a strong resistance to X-ray irradiation 49 (Malaise et al 1986) . 9L is the most widely used of all rat brain tumour models for research as 50 well as a preclinical model used in brain radiotherapy and has been utilized in various treatment 51 studies for over 30 years (Barth 1998 ).
52
In developed countries, radiation is used to treat half of all cancer patients (Baskar et al 2012) .
53
Photons generated by linear accelerators and X-ray tubes can be used to treat a broad range of however, due to location, function and more specifically, the repair mechanisms employed by the 60 cell to correct radiation damage.
61
Equally important to the success of cancer treatment is the capability to image cancers, both for .
75
These nanoparticles produce more secondary electrons, auger electrons, ROS species, and 76 characteristic X-rays that induce even more localized ionising radiation damage to cells and lead
77
to radiosensitization. For use in the biological environment, biocompatibility and preferential
78
cancer cell uptake also become useful properties for nanoparticle radio-sensitising agents.
79
Nanomaterials which are the most commonly studied for use in radiotherapy or radiology 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t (Maggiorella et al 2012) , and gadolinium (Z=64), (Kotb et 
107
There are however, some concerns over the toxicity of some gadolinium-based agents. The 
METHODS AND MATERIALS

140
Nanoparticle Preparation and Characterization
141
Thulium (III) oxide nanoparticles (99.9% trace metals basis) were obtained from Sigma Aldrich.
142
For initial characterization, a sample of the thulium oxide nanoparticles were analysed with X-143 ray diffraction (XRD) using a GBC MMA X-ray diffraction system scanning between 20 to 90 144 degrees to determine structural information and mean particle size. The nanoparticle sample was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t counted and compared with the initial seeding number to determine the plating efficiency (PE).
175
For each group, the surviving fraction (SF) was calculated by taking the ratio of the PE of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t size was determined to be 42.52 nm using Tracers V6.6.9 which employs Scherrer's equation 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Thulium oxide.
305
After 24 hrs of exposure, the thulium oxide NPs are internalized into the cell and as a result,
306
there is a reduction in the cell survival of 9L gliosarcoma. The toxicity towards the 9L cancer 307 cells tends to increase with concentration until saturation after 100 μg/mL. We believe that this is 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t that is represented by the quadratic component, β.
329
The cell sensitivity enhancement ratio (SER) at 10% SF was found to be 1.32 for thulium oxide 330 nanoparticles when considering the only effect of the radiation enhancement due to the 331 nanoparticle, and not including intrinsic toxicity. This is comparable with other nano-structured nanoparticles.
338 Figure 7 shows an assessment of DNA damage in the form of double-strand DNA breaks (green) 339 in 9L cells using a Mouse Anti-γ-H2AX IgG1 primary antibody that was introduced to fixed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t 
349
The formation of γ-H2AX foci at 8 Gy tends to increase in the presence of nanoparticles. This is 350 evident in Figure 7 by the greater occurrence of enlarged foci that corresponds to clustered, more 
356
CT Contrast Enhancement
357
The average CT number (HU) was measured using ImageJ for various concentrations of thulium 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In a separate in vivo study, thulium nanoparticles (40 µg or 2 µL and concentration of 20 371 mg/mL) were injected into the caudate nucleus of 9-to 10-week-old Fischer rats in order to 372 target the brain cancer at day 12 following tumour implantation. In Figure 9 , the evolution of the 373 nanoparticles' uptake and position is shown.
374
In Fig. 9A , the thulium nanoparticles are initially localized around the injection point at 5 mins 375 following injection. By 10 mins, the nanoparticles have distributed around and inside the tumour 376 volume (Fig. 9B) and by 25 mins, the nanoparticles are cleared from the tumour (Fig. 9C) . The 377 rodents monitored to 24 hrs showed no trace of the thulium particles. We also observed no 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We have shown that the Tm 2 O 3 nanoparticles are well internalized into the brain cancer cells. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t They do however, show a slight toxicity towards them to induce at maximum 40% survival after 399 3 weeks following an initial 24 hr exposure with concentrations up to 500 µg/mL. 
406
Our findings indicate thulium nanoparticles are good candidates for image-guided radiotherapies.
407
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